1Baxter E J,Scott LM,Campbell PJ. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders[J].The Lancet,2005,(9464):1054-1061. 被引量：1
2Randi ML,Putti MC,Scapin M. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative[J].Blood,2006,(10):3600-3602. 被引量：1
3Vassiliou GS,Campbell PJ,Li J. An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation[J].Haematologica,2006,(08):1100-1104. 被引量：1
4Beer PA,Campbell PJ,Scott LM. MPL mutations in myeloproliferative disorders:analysis of the PT-1 cohort[J].Blood,2008,(01):141-149.doi:10.1182/blood-2008-01-131664. 被引量：1
5Villeval JL,James C,Pisani DF. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients[J].Seminars in Thrombosis and Hemostasis,2006,(4Pt 2):341-351. 被引量：1
6Passamonti F,Rumi E. Clinical relevance of JAK2(V617F) mutant allele burden[J].Haematologica,2009,(01):7-10. 被引量：1
7Wadleigh M,Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria[J].International Journal of Hematology,2010,(02):174-179. 被引量：1
8Harrison CN,Bareford D,Butt N. Guideline for investigation and management of adults and children presenting with a thrombocytosis[J].British Journal of Haematology,2010,(03):352-375. 被引量：1
9Vannucchi AM,Guglielmelli P,Tefferi A. Advances in understanding and management of myeloproliferative neoplasms[J].CA:A Cancer Journal for Clinicians,2009,(03):171-191. 被引量：1
